Trials
2 active
3 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval”In the company’s words, NCT06659549 on ClinicalTrials.gov
- Main trialPhase 2
- “Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the…”In the company’s words, NCT06659549 on ClinicalTrials.gov
Other drugs for Geographic Atrophy of the Macula
- TinlarebantBelite Bio, Inc · Phase 3
- VonaprumentAnnexon, Inc. · Phase 3
- CemdisiranRegeneron · Phase 3
- PozelimabRegeneron · Phase 3
- BevemipretideMighty Therapeutics Inc. · Phase 2/3
- JNJ-81201887Johnson & Johnson (Janssen) · Phase 2/3
Coming up2
- 30 Mar 2028Phase 2 trial completes · ClinicalTrials.gov
- 30 Apr 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovCompletion date moved: 2027-03-30 to 2028-03-30 · ClinicalTrials.gov NCT06659549
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Mar 2028 | A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD | |
| Phase 2Not yet recruiting | 30 Apr 2028 | A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease | |
| Phase 1Completed | 18 Sep 2025 | A SINGLE CENTER, 5-PART STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF GAL-101 SALT IN HEALTHY ADULT AND ELDERLY PARTICIPANTS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026